Biogen Portfolio

Multiple sclerosis (MS) is a life-long, heterogeneous disease and a patient’s therapeutic needs are likely to change across a lifetime.1 

Today there are a number of disease-modifying therapies (DMTs) for RRMS to choose from.1

With expanding treatment choice, comes the need to plan how best to select, customise and sequence disease-modifying therapies (DMTs) to best control and manage disease at many time points.1 

Life-long RRMS treatment plans need to be customised per patient.1,2 Therapy choice should be tailored to patient’s needs and disease activity.3,4 At any timepoint, choice of therapy needs to consider aspects of the chosen DMT such as its benefit-risk profile, evidence-base and mode of action (MoA) – as well as its flexibility for switch of therapy.5,6 

Biogen-29300. Date of preparation: November 2019